Although California is intending to produce insulin for its own population, efforts to meet demand will hardly be a match for the big drugmakers already supplying the state, says Sydbank analyst Søren Løntoft Hansen. In all likelihood, the end product would be both more expensive and based on older research.
In the analyst’s assessment, the initiative will therefore have little effect on Novo Nordisk.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Head of Regulatory Services Denmark 
Antibody Engineering Scientist 
Experienced Biostatistician 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Senior Evidence Generation Manager 
GMP Compliance Consultant for Eltronic in Ballerup 
Snr. Talent Acquisition Partner, Devoteam 
Lead Auditor – Senior Quality Assurance Specialist 
Scientist Radiochemistry 
Global Quality Director (Business Unit Quality Lead) 
Clinical Biometrics Oversight Lead 
Senior Clinical Trial Manager - Black Swans Exist